Make an impact today!  

Previous slide
Next slide
Previous slide
Next slide

Author Archives: pancreatica

Mitazalimab receives orphan Status for pancreatic cancer

Mitazalimab is a monoclonal antibody that targets CD40, a protein that is expressed on the surface of many types of cancer cells. CD40 signaling is thought to play a role in tumor growth and metastasis. Mitazalimab works by blocking CD40 signaling, which can lead to tumor cell death. The FDA has granted orphan drug designation […]

Possible new treatments for pancreatic cancer

Scientists have conducted a study, published in the journal Nature, that found pancreatic cancer cells rely on a molecule called uridine for energy when they are deprived of glucose. Uridine is a type of sugar that is not normally used by healthy cells. The researchers found that pancreatic cancer cells have a higher level of […]

Early promise for mRNA vaccine that helps program the body to fight pancreatic cancer

Studies have found an mRNA vaccine that programs the body to fight pancreatic cancer shows early promise. In a small clinical trial, half of the patients who received the vaccine did not have a recurrence of the tumor a year and a half later. The trial was published in the journal Nature on May 10, […]

Abraxane and Gemcitabine for Advanced Pancreatic Cancer

One of our favorite pancreatic cancer researchers, Dr. Daniel Von Hoff of TGen in Arizona – together with researchers from the Virginia G Piper Cancer Center – is reporting encouraging clinical trials results for those with advanced pancreatic cancer (ductal adenocarcinoma of the pancreas) treated with a combination of Abraxane plus gemcitabine. This MPACT (Metastatic […]

The Enzyme Returns: L-asparaginase encased in red blood cells for pancreatic cancer

In late March 2017, the French biotech firm Erytech presented results of a IIb clinical trial of eryaspase (trade name: GRASPA) which is the enzyme l-asparaginase encapsulated in red blood cells as added to gemcitabine or FOLFIRINOX treatment regimens for patients with advanced pancreatic cancer (ductal adenocarcinoma of the pancreas), versus these standard therapies alone. […]